Clinical Application of SARS-CoV-2 IgM and IgG Antibody Detection Using the Colloidal Gold Immunochromatography Assay
<div xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="section"> <a class="named-anchor" id="d1449689e281"> <!-- named anchor --> </a> <h5 class="section-title...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Compuscript Ltd
2023-11-01
|
| Series: | Zoonoses |
| Online Access: | https://www.scienceopen.com/hosted-document?doi=10.15212/ZOONOSES-2023-0020 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | <div xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="section">
<a class="named-anchor" id="d1449689e281">
<!--
named anchor
-->
</a>
<h5 class="section-title" id="d1449689e282">Objective:</h5>
<p dir="auto" id="d1449689e284">The COVID-19 pandemic, which was caused by SARS-CoV-2, has had a significant effect
on global public health, economies, and societies worldwide. Serum antibody testing
is a critical method for the diagnosis of COVID-19 and can complement RT-PCR in the
diagnosis of COVID-19 patients; however, the performance of rapid antibody assays
in the clinical setting has not been established.
</p>
</div><div xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="section">
<a class="named-anchor" id="d1449689e286">
<!--
named anchor
-->
</a>
<h5 class="section-title" id="d1449689e287">Methods:</h5>
<p dir="auto" id="d1449689e289">Rapid antibody assays were evaluated by investigating 296 COVID-19-positive individuals
and 542 negative individuals confirmed by clinical diagnosis. The clinical diagnostic
results were used as controls to evaluate the sensitivity, specificity, positive predictive
value (PPV), negative predictive value (NPV), kappa, and 95% confidence interval (CI)
of the rapid tests.
</p>
</div><div xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="section">
<a class="named-anchor" id="d1449689e291">
<!--
named anchor
-->
</a>
<h5 class="section-title" id="d1449689e292">Result:</h5>
<p dir="auto" id="d1449689e294">IgM-positivity had a sensitivity of 86.1% and specificity of 99.1%. IgG-positivity
had a sensitivity of 86.5% and specificity of 98.7%. The sensitivity of combined IgM-
and IgG-positivity in clinically confirmed patients was 73.1% in the early stage (1-7
days after symptom onset) and reached 99% 15 days after symptom onset. The concordance
between rapid antibody-positive tests and clinical diagnosis-positivity had a kappa
value of 0.93. In addition, the false-positive rate of IgM and IgG combined nucleic
acid detection was 30% in the early stage.
</p>
</div><div xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="section">
<a class="named-anchor" id="d1449689e296">
<!--
named anchor
-->
</a>
<h5 class="section-title" id="d1449689e297">Conclusion:</h5>
<p dir="auto" id="d1449689e299">The combined use of IgM and IgG could serve as a more suitable alternative detection
method for patients with COVID-19. The rapid antibody test can be considered as an
excellent supplementary approach for detecting SARS-CoV-2 in clinical application.
</p>
</div> |
|---|---|
| ISSN: | 2737-7466 2737-7474 |